Buys
Open market- Shares
- Avg price
- Total value
Kenneth Galbraith - Chair & CEO, Director at Zymeworks Inc.
Issuer-level insider activity
- Role
- Chair & CEO, Director
- Issuer symbol
- ZYME on Nasdaq
- Entity type
- Individual
- SEC filing history
- Open SEC filing history
Identity
1 identity field
Source evidence
1 source field
Past-year transaction volume for Kenneth Galbraith in Zymeworks Inc.
Sells
Open market- Shares
- -132,295
- Avg price
- $25.23
- Total value
- -$3,337,971
Net
Past year- Shares
- -132,295
- Share %
- -100%
- Total value
- -$3,337,971
Reported holdings for Kenneth Galbraith in Zymeworks Inc.
Form 4 holding
Chair & CEO, Director
Zymeworks Inc.
- Security class
- Common Stock
- Shares / value
- 226,842
- Estimated value
- $5,143,302
- Report date
- 12 Jan 2026
- Price
- $22.67
- Ownership
- Direct
Form 4 holding
Chair & CEO, Director
Zymeworks Inc.
- Security class
- Restricted Stock Unit
- Shares / value
- 144,000
- Estimated value
- $2,865,427
- Report date
- 12 Jan 2026
- Price
- $14.92
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chair & CEO, Director
Zymeworks Inc.
- Security class
- Performance Stock Unit
- Shares / value
- 222,000
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chair & CEO, Director
Zymeworks Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 216,000
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Kenneth Galbraith in Zymeworks Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.